Poop pills may prevent dangerous side effects of cancer immunotherapy
NCT ID NCT04163289
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This early-stage trial tests whether taking capsules containing processed stool from healthy donors can prevent severe immune-related side effects in people with advanced kidney cancer receiving a combination of two immunotherapy drugs (ipilimumab and nivolumab). The study involves 20 participants who will take the fecal transplant capsules before and during their first two cycles of immunotherapy. The main goal is to see if this approach is safe and reduces the occurrence of serious colitis and other immune-related adverse events, helping patients stay on treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Fecal microbiota transplantation (FMT) capsules from healthy donors
What this could lead to
If it works, this approach could help patients tolerate powerful immunotherapy combinations better, allowing them to continue treatment and potentially improve outcomes.
What could go wrong
This is a very early phase 1 trial with only 20 participants, so results may not apply broadly. The safety and effectiveness of FMT for this purpose are still unknown.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RENAL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
London Regional Cancer Program of the Lawson Health Research Institute
London, Ontario, N6A 5W9, Canada